JP6227629B2 - ヒトアミリン類似体 - Google Patents

ヒトアミリン類似体 Download PDF

Info

Publication number
JP6227629B2
JP6227629B2 JP2015506251A JP2015506251A JP6227629B2 JP 6227629 B2 JP6227629 B2 JP 6227629B2 JP 2015506251 A JP2015506251 A JP 2015506251A JP 2015506251 A JP2015506251 A JP 2015506251A JP 6227629 B2 JP6227629 B2 JP 6227629B2
Authority
JP
Japan
Prior art keywords
nmol
vehicle
rats
compared
subcutaneous injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015506251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514737A (ja
JP2015514737A5 (OSRAM
Inventor
キルステン・ダール
ラウゲ・シェーファー
トーマス・クルーセ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2015514737A publication Critical patent/JP2015514737A/ja
Publication of JP2015514737A5 publication Critical patent/JP2015514737A5/ja
Application granted granted Critical
Publication of JP6227629B2 publication Critical patent/JP6227629B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
JP2015506251A 2012-04-19 2013-04-19 ヒトアミリン類似体 Active JP6227629B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12164692.1 2012-04-19
EP12164692 2012-04-19
US201261637806P 2012-04-24 2012-04-24
US61/637,806 2012-04-24
PCT/EP2013/058165 WO2013156594A1 (en) 2012-04-19 2013-04-19 Human amylin analogues

Publications (3)

Publication Number Publication Date
JP2015514737A JP2015514737A (ja) 2015-05-21
JP2015514737A5 JP2015514737A5 (OSRAM) 2017-09-21
JP6227629B2 true JP6227629B2 (ja) 2017-11-08

Family

ID=49382960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015506251A Active JP6227629B2 (ja) 2012-04-19 2013-04-19 ヒトアミリン類似体

Country Status (7)

Country Link
US (2) US8575091B1 (OSRAM)
EP (2) EP2838914B1 (OSRAM)
JP (1) JP6227629B2 (OSRAM)
CN (1) CN104395338B (OSRAM)
ES (1) ES2640285T3 (OSRAM)
PL (1) PL2838914T3 (OSRAM)
WO (1) WO2013156594A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
EA035791B1 (ru) * 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
CN106928086B (zh) 2015-12-31 2019-05-31 深圳翰宇药业股份有限公司 一种长链化合物的制备方法
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
US11028137B2 (en) 2017-02-01 2021-06-08 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
JP2020510028A (ja) 2017-03-08 2020-04-02 インターシア セラピューティクス，インコーポレイティド 薬物送達デバイスから吐き気誘発性化合物の投与のための装置及び方法
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
KR102911883B1 (ko) 2018-10-11 2026-01-13 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
US11666634B2 (en) * 2019-04-24 2023-06-06 The Board Of Regents Of The University Of Texas System Methods and compositions for management of gastrointestinal disorders
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
MX2022014309A (es) * 2020-05-15 2022-12-07 Lilly Co Eli Compuestos de insulina acilada de accion temporal prolongada.
JP7674630B2 (ja) * 2020-12-08 2025-05-12 通化安睿特生物製薬股▲フェン▼有限公司 組換えタンパク質を精製する方法
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
CN116621944A (zh) * 2022-02-10 2023-08-22 成都奥达生物科技有限公司 一种长效肝炎病毒进入抑制剂
MX2024005969A (es) 2022-05-30 2024-06-11 Zealand Pharma As Formulaciones liquidas de analogos de amilina.
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
TW202500183A (zh) 2023-06-15 2025-01-01 丹麥商諾佛 儂迪克股份有限公司 包括環糊精的醫藥調配物
TW202545982A (zh) * 2024-02-07 2025-12-01 大陸商江蘇恆瑞醫藥股份有限公司 胰島澱粉樣多肽類似物及其醫藥用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07509008A (ja) 1993-05-12 1995-10-05 ユニバーシティ・オブ・シンシナティ アミリン・アンタゴニストおよびアゴニスト
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
EP1053001B1 (en) * 1998-02-13 2010-12-15 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
DE602005021858D1 (de) 2004-02-11 2010-07-29 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
AU2005295043A1 (en) * 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
JP5252435B2 (ja) * 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
CN102292346B (zh) * 2009-01-22 2015-12-02 关键生物科学有限公司 肥胖的治疗
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
KR102066987B1 (ko) * 2011-06-10 2020-01-16 노보 노르디스크 에이/에스 폴리펩티드

Also Published As

Publication number Publication date
CN104395338B (zh) 2019-05-10
PL2838914T3 (pl) 2017-11-30
EP3109256A1 (en) 2016-12-28
US20130281363A1 (en) 2013-10-24
US20140087995A1 (en) 2014-03-27
US8575091B1 (en) 2013-11-05
CN104395338A (zh) 2015-03-04
JP2015514737A (ja) 2015-05-21
ES2640285T3 (es) 2017-11-02
EP2838914A1 (en) 2015-02-25
WO2013156594A1 (en) 2013-10-24
EP2838914B1 (en) 2017-06-14
US9023789B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
JP6247205B2 (ja) ポリペプチド
US9023789B2 (en) Amylin analogs and pharmaceutical compositions thereof
JP5703226B2 (ja) アミリン誘導体
EP2036923A1 (en) Improved derivates of amylin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170509

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20170809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170915

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171011

R150 Certificate of patent or registration of utility model

Ref document number: 6227629

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250